옵션 체인은 다양한 행사가격과 만기일에 대한 NKGen Biotech의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 NKGen Biotech에 대한 시장 심리를 평가합니다..

NKGen Biotech (OTC:NKGN) 주식, 옵션 체인

NKGen Biotech

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

NKGen Biotech Inc

Icon Energy Corp. ("Icon" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, is pleased to announce the successful delivery of the M/V Charlie to its fleet.
Delivery. On June 21, 2025, Icon took delivery of the M/V Charlie, a 2020-built, scrubber-fitted, eco Ultramax dry bulk carrier, it had agreed to bareboat charter-in from an unaffiliated third party, as previously announced on March 24, 2025.
Charter. The M/V Charlie has been time chartered-out to a reputable dry bulk operator for a period of 9 to 12 months, at a floating daily hire rate linked to the Baltic Supramax Index. In addition to the daily hire rate, Icon will also receive a share of the fuel cost savings to be realized by the charterer through the use of the vessel's scrubber. The time charter commenced immediately upon delivery of the M/V Charlie to Icon.

News

ICON

Icon Energy Adds Scrubber-Fitted M/V Charlie To Fleet, Secures 9-12 Month Time Charter; Icon Will Also Receive A Share Of The Fuel Cost Savings To Be Realized By The Charterer Through The Use Of The Vessel's Scrubber

Cantor Fitzgerald analyst Derek Soderberg reiterates SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) with a Overweight and maintains $2 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on SES AI, Maintains $2 Price Target

Management

WRAP

Wrap Technologies Appoints Gerald "Jerry" Ratigan as CFO

Compass Point analyst Ed Engel initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Neutral rating and announces Price Target of $205.

Initiation

CRCL

Compass Point Initiates Coverage On Circle Internet Group with Neutral Rating, Announces Price Target of $205

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.70</td>
<td align="right">2.30</td>
<td align="right">1.07</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">245.43</td>
<td align="right">2.55</td>
<td align="right">1.04</td>
<td>73.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.26</td>
<td align="right">0.44</td>
<td align="right">0.86</td>
<td>219.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">104.75</td>
<td align="right">0.86</td>
<td align="right">0.82</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">144.52</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.23</td>
<td align="right">0.17</td>
<td align="right">0.40</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.66</td>
<td align="right">0.50</td>
<td align="right">0.37</td>
<td>13.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.67</td>
<td align="right">0.27</td>
<td align="right">0.33</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.42</td>
<td align="right">0.18</td>
<td align="right">0.22</td>
<td>14.2K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.25</td>
<td align="right">-0.78</td>
<td align="right">-0.91</td>
<td>436.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 24, 2025

Biotech

General

ENVB

Enveric Biosciences Announces Additional Data Indicating EB-003 Acts As An Agonist Of Serotonin Receptor 5-HT1B

PSTG

Pure Storage Appoints Tarek Robbiati As CFO, Succeeding Kevan Krysler, Effective Immediately

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.
The investors in the Offering include existing healthcare-focused institutional investors, executive officers, and members of the Company's Board of Directors.

Offerings

CADL

Candel Therapeutics Announces $15M Registered Direct Offering Of 3.2M Shares At $4.67 Per Share

Deutsche Bank analyst Matthew Niknam maintains CommScope Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) with a Hold and raises the price target from $6 to $7.5.

COMM

Deutsche Bank Maintains Hold on CommScope Holding Co, Raises Price Target to $7.5

22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category. The agreement includes a merchandising agreement to potentially expand the availability of Pinnacle products to include other retail and c-store chains.
The new agreement includes two partner VLN products, Pinnacle VLN&#xAE; Gold cigarettes and Pinnacle Menthol VLN&#xAE; cigarettes which will be sold at approximately 1,700 stores across 27 states. Sales to customers are expected to begin in late summer and early fall of 2025, with stocking orders in advance, as state approvals are secured.

XXII

22nd Century Announces Updates To Pinnacle Product Manufacturing And Marketing Agreement With Top-5 C-Store Chain Customer; Launches Pinnacle VLN And Moist Snuff Products In More Than 1,700 Stores Across 27 States

<a href="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm" title="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm">https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm</a>

Guidance

Schlumberger N.V. Says Looking Broadly Across Energy Markets, There Has Been A Lot Of Uncertainty This Quarter; Commitment To Returning A Minimum Of $4B To Shareholders In 2025 Is Unchanged

Cantor Fitzgerald analyst Matthew Prisco maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Overweight and raises the price target from $90 to $105.

Cantor Fitzgerald Maintains Overweight on Teradyne, Raises Price Target to $105

Homeowners have on average, $181,000 in equity. This new product helps them access it before transitioning to a new home
DETROIT, June 24, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=3636688888&amp;u=https%3A%2F%2Frocket.com%2Fmortgage%2F&amp;a=Rocket+Mortgage">Rocket Mortgage</a>, the nation's largest mortgage lender and a part of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=1515700121&amp;u=https%3A%2F%2Fwww.rocketcompanies.com%2F&amp;a=Rocket+Companies">Rocket Companies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), today announced the launch of bridge loans – a strategic solution designed to help buyers wrestle back control in today's competitive housing market. This new product allows current homeowners to use equity to compete shoulder-to-shoulder with cash buyers – allowing them to purchase their next primary residence before selling their current one. This provides both financial flexibility and eliminates the uncertainty and reluctance of home sellers that often comes with so-called 'contingent' offers.
With high home prices and tight housing inventory, many buyers struggle to compete without first selling – leading to delays and missed opportunities. Yet the average homeowner has $181,000 in untapped equity, a powerful resource to make a strong offer.¹ &nbsp;Rocket Mortgage's bridge loan unlocks that equity upfront, providing funds for a down payment or closing costs in the interim.

Rocket Mortgage Launches Bridge Loans To Help Homeowners Access Equity And Compete With Cash Buyers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Cantor Fitzgerald analyst Matthew Prisco maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Neutral and lowers the price target from $110 to $90.

ONTO

Cantor Fitzgerald Maintains Neutral on Onto Innovation, Lowers Price Target to $90

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis
No new safety signals observed
SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN&#xAE;&nbsp;(valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025.
The Phase 3 GENEr8-1 trial demonstrated that durable bleed control and sustained factor VIII (FVIII) expression were maintained five years after treatment with ROCTAVIAN. FVIII activity remained consistent with previously reported results, and no new safety signals were observed. Across the entire trial, no participants developed FVIII inhibitors or experienced thromboembolic events, and there were no treatment-related malignancies across the five years of the study.

BMRN

BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH

Contracts

ASNS

Actelis Receives Initial Order From A Telecommunications Carrier To Deploy Its GigaLine Solutions

GSK Announces FDA Approval Of Benlysta Autoinjector For children With Active Lupus Nephritis

PPSI

Pioneer Power Solutions Bags ~$10M Award From U.S. Charging-As-A-Service Company To Accelerate e-Boost Deployment

Cantor Fitzgerald analyst Matthew Prisco maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Overweight and raises the price target from $250 to $300.

NVMI

Cantor Fitzgerald Maintains Overweight on Nova, Raises Price Target to $300

Press Releases

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit

Health Care

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida

NKGN

Comments

NKGen Biotech

NKGen Biotech (NKGN) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌